About
This medication is a fixed-dose combination of Dapagliflozin and Linagliptin, indicated for the treatment of type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting glucose excretion in the urine, independent of insulin action. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin hormone levels, thereby enhancing glucose-dependent insulin release from pancreatic beta cells and reducing glucagon secretion from alpha cells. This combination provides complementary actions to improve glycemic control, offering benefits in terms of HbA1c reduction, potential modest weight loss, and blood pressure reduction. It targets multiple pathways involved in glucose homeostasis, making it a potent option for patients requiring comprehensive management of their type 2 diabetes.
Uses
- Management of type 2 diabetes mellitus.
- As an adjunct to diet and exercise.
- To improve glycemic control in adults.
- When monotherapy with either agent is inadequate.
Directions For Use
Take one tablet orally once daily in the morning, with or without food, as directed by your physician.
Benefits
- Effective in lowering blood glucose levels.
- Offers complementary mechanisms of action.
- Potential for modest weight loss.
- May contribute to blood pressure reduction.
- Low risk of hypoglycemia when not combined with insulin/sulfonylureas.
- Convenient once-daily dosing.
Side Effects
- Urinary tract infections
- Genital mycotic infections
- Nasopharyngitis
- Cough
- Diarrhea
- Headache
- Increased urination
- Back pain
- Joint pain
- Dizziness
- Hypotension
- Ketoacidosis (rare, SGLT2 inhibitor-related)
Safety Measures
- Alcohol - Limit alcohol intake as it can increase the risk of dehydration and ketoacidosis, particularly with SGLT2 inhibitors.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse renal effects on the developing fetus. Consult a doctor.
- Breastfeeding - It is unknown if these drugs are excreted in human milk. Avoid use during breastfeeding or consult a healthcare provider.
- Liver - No dose adjustment is typically required for Linagliptin in hepatic impairment. Dapagliflozin also generally does not require adjustment.
- Kidney - Dapagliflozin is not recommended for patients with eGFR <25 mL/min/1.73m². Linagliptin does not require dose adjustment in renal impairment.
- Lung - No specific contraindications related to lung conditions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!